Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SL Science HoldingSLBT -1.85%12 Earnings per Share (Diluted) is $-0.01 as of Dec. 2025. GuruFocus rates SLBT with a GF Score™ of 12/100. The stock has 5 warning signs investors should review. Among 1,161 Biotechnology companies, SL Science Holding ranks worse than 86132.56% on this metric.
SL Science Holding's EPS (Basic) for the
six
months ended in Dec. 2025 was $-0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.01.
SL Science Holding (NAS:SLBT) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
SL Science Holding Earnings per Share (Diluted) Related Terms
SL Science Holding Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for SL Science Holding's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SL Science Holding Earnings per Share (Diluted) Chart
SL Science Holding Annual Data
Trend
Dec23
Dec24
Dec25
Earnings per Share (Diluted)
0.00
-0.00
-0.01
SL Science Holding Semi-Annual Data
Dec23
Jun24
Dec24
Jun25
Dec25
Earnings per Share (Diluted)
0.00
-0.00
-0.00
-0.00
-0.00
SLBT vs DMRA, BCAX, TYRA: Earnings per Share (Diluted) Comparison
For the Biotechnology subindustry, SL Science Holding's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SL Science Holding PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SL Science Holding's PE Ratio distribution charts can be found below:
* The bar in red indicates where SL Science Holding's PE Ratio falls into.
SL Science Holding Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
SL Science Holding's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-0.01
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-0.01 mean?
SL Science Holding (SLBT) has a Earnings per Share (Diluted) of $-0.01 as of Dec. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on SL Science Holding and its competitors. According to the industry distribution chart, SL Science Holding ranks #999999 out of 1161 companies in the Biotechnology industry.
Is SL Science Holding's Earnings per Share (Diluted) too high?
SL Science Holding's current Earnings per Share (Diluted) is $-0.01. Based on the distribution chart, SL Science Holding ranks #999999 out of 1161 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SL Science Holding has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does SL Science Holding's Earnings per Share (Diluted) compare to DMRA and BCAX?
According to the Biotechnology industry distribution chart, SL Science Holding ranks #999999 out of 1161 companies for Earnings per Share (Diluted). This places SL Science Holding in the lower half of its industry. The industry median Earnings per Share (Diluted) is 16.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Biotechnology company?
The median Earnings per Share (Diluted) among Biotechnology companies is 16.20, based on 1,161 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on SL Science Holding and its competitors. For the Biotechnology industry, the median Earnings per Share (Diluted) is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SL Science Holding's current Earnings per Share (Diluted) is $-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SL Science Holding stock overvalued right now?
SL Science Holding (SLBT) has a current Earnings per Share (Diluted) of $-0.01. The current Earnings per Share (Diluted) is $-0.01. SL Science Holding's overall GF Score™ is 12/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For SL Science Holding (SLBT), the current Earnings per Share (Diluted) is $-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.
12GF Score
Get the complete analysis for SLBT
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLBT has been successfully added to your 
